Alkem Laboratories Limited has announced the acquisition of 64,02,018 equity shares in its subsidiary, Enzene Biosciences Limited, on a rights basis. The acquisition, priced at ₹468.60 per equity share, amounts to a total consideration of ₹299,99,85,634.80 (approximately ₹300 crore). The equity shares were allotted by Enzene on December 26, 2025. Enzene Biosciences Limited, engaged in the research, development, manufacturing, and out-licensing of biosimilar products, as well as contract development and manufacturing for biosimilars and novel biologics, reported a turnover of ₹363.62 crore for the financial year ended March 31, 2025. This acquisition is intended to meet Enzene's capital expenditure and working capital requirements. Following the allotment, Alkem Laboratories Limited's shareholding in Enzene Biosciences Limited has increased to 99.61% of the total equity share capital. The acquisition does not fall within the purview of related party transactions. Enzene Biosciences Limited was incorporated on August 28, 2006, and operates within the biosimilars and biologics contract manufacturing industry.
